Concert Pharmaceuticals Inc. (NASDAQ:CNCE)‘s stock had its “buy” rating reiterated by analysts at Stifel Nicolaus in a research report issued to clients and investors on Tuesday. They currently have a $23.00 price objective on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 131.85% from the company’s previous close.
Other research analysts have also issued research reports about the stock. Brean Capital restated a “buy” rating on shares of Concert Pharmaceuticals in a research report on Monday, July 11th. Zacks Investment Research lowered shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 11th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $26.43.
Concert Pharmaceuticals (NASDAQ:CNCE) opened at 9.92 on Tuesday. The company has a 50 day moving average price of $10.37 and a 200 day moving average price of $11.98. The stock’s market capitalization is $220.49 million. Concert Pharmaceuticals has a 12 month low of $9.47 and a 12 month high of $25.04.
Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.03. Concert Pharmaceuticals had a negative net margin of 289.85% and a negative return on equity of 29.09%. Equities research analysts predict that Concert Pharmaceuticals will post ($2.51) earnings per share for the current year.
A number of institutional investors have recently bought and sold shares of the company. BVF Inc. IL boosted its position in Concert Pharmaceuticals by 23.4% in the first quarter. BVF Inc. IL now owns 2,755,318 shares of the company’s stock valued at $37,638,000 after buying an additional 523,304 shares during the last quarter. Acadian Asset Management LLC boosted its position in Concert Pharmaceuticals by 168.7% in the second quarter. Acadian Asset Management LLC now owns 275,138 shares of the company’s stock valued at $3,091,000 after buying an additional 172,735 shares in the last quarter. Ramsey Quantitative Systems boosted its position in Concert Pharmaceuticals by 48.5% in the first quarter. Ramsey Quantitative Systems now owns 35,281 shares of the company’s stock valued at $482,000 after buying an additional 11,517 shares in the last quarter. GSA Capital Partners LLP boosted its position in Concert Pharmaceuticals by 230.9% in the second quarter. GSA Capital Partners LLP now owns 150,748 shares of the company’s stock valued at $1,693,000 after buying an additional 105,187 shares in the last quarter. Finally, Prudential Financial Inc. boosted its position in Concert Pharmaceuticals by 11.4% in the first quarter. Prudential Financial Inc. now owns 241,790 shares of the company’s stock valued at $3,303,000 after buying an additional 24,690 shares in the last quarter. Hedge funds and other institutional investors own 61.68% of the company’s stock.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.
Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.